Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
TP53 mutations and TET2 deficiency cooperate to drive leukemogenesis and establish an immunosuppressive environment
Pu Zhang, … , Omar Abdel-Wahab, Rosa Lapalombella
Pu Zhang, … , Omar Abdel-Wahab, Rosa Lapalombella
Published March 20, 2025
Citation Information: J Clin Invest. 2025;135(10):e184021. https://doi.org/10.1172/JCI184021.
View: Text | PDF
Research Article Hematology Inflammation Oncology

TP53 mutations and TET2 deficiency cooperate to drive leukemogenesis and establish an immunosuppressive environment

  • Text
  • PDF
Abstract

Mutations and deletions in TP53 are associated with adverse outcomes in patients with myeloid malignancies, and there is an urgent need for the development of improved therapies for TP53-mutant leukemias. Here, we identified mutations in TET2 as the most common co-occurring mutation in patients with TP53-mutant acute myeloid leukemia (AML). In mice, combined hematopoietic-specific deletion of TET2 and TP53 resulted in enhanced self-renewal compared with deletion of either gene alone. Tp53/Tet2 double-KO mice developed serially transplantable AML. Both mice and patients with AML with combined TET2/TP53 alterations upregulated innate immune signaling in malignant granulocyte-monocyte progenitors, which had leukemia-initiating capacity. A20 governs the leukemic maintenance by triggering aberrant noncanonical NF-κB signaling. Mice with Tp53/Tet2 loss had expansion of monocytic myeloid-derived suppressor cells (MDSCs), which impaired T cell proliferation and activation. Moreover, mice and patients with AML with combined TP53/TET2 alterations displayed increased expression of the TIGIT ligand, CD155, on malignant cells. TIGIT-blocking antibodies augmented NK cell–mediated killing of Tp53/Tet2 double-mutant AML cells, reduced leukemic burden, and prolonged survival in Tp53/Tet2 double-KO mice. These findings describe a leukemia-promoting link between TET2 and TP53 mutations and highlight therapeutic strategies to overcome the immunosuppressive bone marrow environment in this adverse subtype of AML.

Authors

Pu Zhang, Ethan C. Whipp, Sarah J. Skuli, Mehdi Gharghabi, Caner Saygin, Steven A. Sher, Martin Carroll, Xiangyu Pan, Eric D. Eisenmann, Tzung-Huei Lai, Bonnie K. Harrington, Wing Keung Chan, Youssef Youssef, Bingyi Chen, Alex Penson, Alexander M. Lewis, Cynthia R. Castro, Nina Fox, Ali Cihan, Jean-Benoit Le Luduec, Susan DeWolf, Tierney Kauffman, Alice S. Mims, Daniel Canfield, Hannah Phillips, Katie E. Williams, Jami Shaffer, Arletta Lozanski, Tzyy-Jye Doong, Gerard Lozanski, Charlene Mao, Christopher J. Walker, James S. Blachly, Anthony F. Daniyan, Lapo Alinari, Robert A. Baiocchi, Yiping Yang, Nicole R. Grieselhuber, Moray J. Campbell, Sharyn D. Baker, Bradley W. Blaser, Omar Abdel-Wahab, Rosa Lapalombella

×

Figure 3

Tp53/Tet2 double-KO mice develop AML characterized by expansion of granulocyte macrophage progenitors.

Options: View larger image (or click on image) Download as PowerPoint

Tp53/Tet2 double-KO mice develop AML characterized by expansion of gran...
(A) Representative flow cytometry analysis of lineages of CD45dimSSClo cells in spleens from Tp53–/–Tet2–/–, Tet2–/–, Tp53–/–, and WT mice at the time of sacrifice (4 months of age). (B) Representative flow cytometry analysis of CD11b+cKIT+ cells in peripheral blood from moribund 4-month-old Tp53–/–Tet2–/– mice and age-matched controls. (C) Frequency of CD11b+ and cKIT+ cells among CD45.2+ cells in peripheral blood of moribund 4-month-old Tp53–/–Tet2–/– mice and age-matched controls. n = 3–6 mice/group. *P < 0.05. Mean ± SEM. ANOVA with Dunnett’s test was used for significance. (D) Top: Immunohistochemical staining of spleens of representative moribund mice for the proteins indicated. Scale bar: 100 μm. Bottom: Wright-Giemsa stain of peripheral blood of Tp53–/–Tet2–/– and littermate WT mice. Data are representative of n = 6 mice/group. Scale bar: 10 μm. (E) Left: Frequencies of long-term hematopoietic stem cells (LT-HSC), multipotent progenitors (MPP), and short-term HSCs (ST-HSC) among bone marrow lineage-negative Sca1+cKIT+ (LSK) cells of 16-week-old mice with the indicated genotypes. Right: Frequencies of common myeloid progenitors (CMP), granulocyte macrophage progenitors (GMPs), and megakaryocyte-erythroid progenitors (MEPs) among bone marrow Lin–Sca-1–cKIT+ cells of 16-week-old mice with the indicated genotypes. n = 3 mice/group; Mean ± SD. ANOVA with Dunnett’s test. (F) Percentage of bone marrow EdU+ GMPs in 16-week-old mice with the indicated genotypes. n = 5 mice/group. *P<0.05. ANOVA with Dunnett’s test was used for significance. Tp53–/–Tet2–/–, Vav-cre Tet2fl/fl Tp53fl/fl; Tet2–/–, Vav-cre Tet2fl/fl; Tp53–/–, Vav-cre Tp53fl/fl; WT, Vav-cre.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts